KalVista Pharmaceuticals, Inc. (KALV)

NASDAQ

$--

(--)

After-Hours

KalVista Pharmaceuticals, Inc. (KALV) Live Price Chart

Last updated: ⁦2026-10-21 23:05:20⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

KalVista Pharmaceuticals, Inc. (KALV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	--
Open	--
Day's High	--
Day's Low	--
Previous Close	--
Volume	--
Average Volume	--
P/E Ratio	--
52-Week High	--
52-Week Low	--
Dividend Yield	--
Earnings Date	--

KalVista Pharmaceuticals, Inc. (KALV) After-Hours Stock Price

KalVista Pharmaceuticals, Inc. (KALV) is trading at $-- in after-hours trading as of --, -- from the regular-session close of $--.

After-hours trading shows how investors are pricing KALV after the regular session closes. The current after-hours price is -- the regular-session close, indicating -- after-hours sentiment.

KalVista Pharmaceuticals, Inc. (KALV) 7-Day Stock Price Change

Over the past seven days, KalVista Pharmaceuticals, Inc. (KALV) moved from $26.95 to $27.00, representing a gain of 0.19% ($0.05).

The stock traded between $26.94 and $27.00 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.

The average daily volume was 2.61 million shares, down versus the previous seven-day period, indicating lower trading activity.

What is KalVista Pharmaceuticals, Inc. (KALV)?

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

KalVista Pharmaceuticals, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	270
Exchange	NASDAQ
Company Website	https://www.kalvista.com

How to Buy KalVista Pharmaceuticals, Inc. (KALV) Stock on MEXC

Eligible investors can buy real shares of KalVista Pharmaceuticals, Inc. (KALV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for KALV and Place Your Order

Open the RealStocks trading page and search for KALV. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is KalVista Pharmaceuticals, Inc. (KALV) stock price today?

KalVista Pharmaceuticals, Inc. (KALV) is currently trading at --, -- from the previous close of --. Intraday prices update in real time during regular trading hours.

2.Is KALV stock going up or down today?

As of --, KALV is trading at --, -- from its previous close of --. The stock has traded between -- and -- during today’s regular session. Past price movements do not guarantee future results.

3.What is KALV pre-market price?

As of --, KALV is trading at -- in pre-market trading, -- from the previous close of --. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is KALV after-hours price?

As of --, KALV is trading at -- in after-hours trading, -- from the regular-session close of --. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is KALV stock trading now?

KALV trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does KALV sit relative to its 52-week high and low?

Over the past 52 weeks, KALV has traded between a low of -- and a high of --. At --, the stock is positioned --% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is KalVista Pharmaceuticals, Inc. in?

KalVista Pharmaceuticals, Inc. (KALV) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is KalVista Pharmaceuticals, Inc.'s market capitalization and where is it listed?

KalVista Pharmaceuticals, Inc. is listed on the NASDAQ exchange with a market capitalization of --. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is KALV valued in terms of P/E ratio and EPS?

KALV trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does KalVista Pharmaceuticals, Inc. pay a dividend?

KalVista Pharmaceuticals, Inc. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.